KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Discontinued Operations (2022 - 2024)

Travere Therapeutics (TVTX) has disclosed Cash from Discontinued Operations for 3 consecutive years, with 7089000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Discontinued Operations fell 16.21% year-over-year to 7089000.0, compared with a TTM value of 7089000.0 through Sep 2025, down 9.7%, and an annual FY2024 reading of 7451000.0, down 116.44% over the prior year.
  • Cash from Discontinued Operations was 7089000.0 for Q4 2024 at Travere Therapeutics, down from 50000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 22064000.0 in Q4 2022 and bottomed at 7089000.0 in Q4 2024.
  • Average Cash from Discontinued Operations over 3 years is 6661000.0, with a median of 50000.0 recorded in 2024.
  • The sharpest move saw Cash from Discontinued Operations crashed 127.65% in 2023, then decreased 16.21% in 2024.
  • Year by year, Cash from Discontinued Operations stood at 22064000.0 in 2022, then plummeted by 127.65% to 6100000.0 in 2023, then dropped by 16.21% to 7089000.0 in 2024.
  • Business Quant data shows Cash from Discontinued Operations for TVTX at 7089000.0 in Q4 2024, 50000.0 in Q3 2024, and 309000.0 in Q2 2024.